ATE247481T1 - Neuartige peptidantagonisten der glutaminsäure- und nmda-rezeptoren - Google Patents

Neuartige peptidantagonisten der glutaminsäure- und nmda-rezeptoren

Info

Publication number: ATE247481T1
Authority: AT; Austria
Prior art keywords: peptide antagonists; glutamic acid; nmda receptors; novel peptide; nmda
Prior art date: 1993-05-14

Application number

AT94916460T

Other languages

English (en)

Inventor

J P Bourguignon

Original Assignee

Neuronz Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-05-14

Filing date

1994-05-16

Publication date

2003-09-15

1994-05-16 Application filed by Neuronz Ltd filed Critical Neuronz Ltd

2003-09-15 Application granted granted Critical

2003-09-15 Publication of ATE247481T1 publication Critical patent/ATE247481T1/de

Links

102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title abstract 2
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title abstract 2
239000005557 antagonist Substances 0.000 title abstract 2
108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 title 1
235000013922 glutamic acid Nutrition 0.000 title 1
239000004220 glutamic acid Substances 0.000 title 1
102000018899 Glutamate Receptors Human genes 0.000 abstract 3
108010027915 Glutamate Receptors Proteins 0.000 abstract 3
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 2
210000004027 cell Anatomy 0.000 abstract 1
210000003169 central nervous system Anatomy 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
210000004498 neuroglial cell Anatomy 0.000 abstract 1
210000002569 neuron Anatomy 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Zoology (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Reproductive Health (AREA)
Molecular Biology (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

AT94916460T 1993-05-14 1994-05-16 Neuartige peptidantagonisten der glutaminsäure- und nmda-rezeptoren ATE247481T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE19939301667A SE9301667D0 (sv)	1993-05-14	1993-05-14	New use
PCT/SE1994/000454 WO1994026301A1 (en)	1993-05-14	1994-05-16	New peptide antagonists at glutamate and nmda receptors

Publications (1)

Publication Number	Publication Date
ATE247481T1 true ATE247481T1 (de)	2003-09-15

Family

ID=20389945

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT94916460T ATE247481T1 (de)	1993-05-14	1994-05-16	Neuartige peptidantagonisten der glutaminsäure- und nmda-rezeptoren

Country Status (12)

Country	Link
US (2)	US5804550A (de)
EP (1)	EP0697886B1 (de)
JP (1)	JP3819932B2 (de)
AT (1)	ATE247481T1 (de)
AU (1)	AU685123B2 (de)
CA (1)	CA2162924C (de)
DE (1)	DE69433058T2 (de)
DK (1)	DK0697886T3 (de)
ES (1)	ES2204916T3 (de)
NZ (1)	NZ266559A (de)
SE (1)	SE9301667D0 (de)
WO (1)	WO1994026301A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6812208B2 (en) *	1993-12-23	2004-11-02	Neuronz Ltd.	Methods to improve neural outcome
WO1995017204A1 (en)	1993-12-23	1995-06-29	Auckland Uniservices Limited	Composition and methods to improve neural outcome
GB9611584D0 (en) *	1996-06-04	1996-08-07	Univ Edinburgh	Neurotransmitters
US20070004641A1 (en) *	2001-05-24	2007-01-04	Neuren Pharmaceuticals Limited	Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate
US7605177B2 (en)	2001-05-24	2009-10-20	Neuren Pharmaceuticals Limited	Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US7714020B2 (en)	2001-05-24	2010-05-11	Neuren Pharmaceuticals Limited	Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
ATE435852T1 (de)	2001-05-24	2009-07-15	Neuren Pharmaceuticals Ltd	Gpe-analoga und peptidomimetika
AU2003218460A1 (en) *	2002-04-05	2003-10-27	Neuronz Biosciences, Inc.	Compositions and methods for immunomodulation
US20060128615A1 (en) *	2002-09-18	2006-06-15	Pierrette Gaudreau	Ghrh analogues
EP1529533A1 (de) *	2003-11-06	2005-05-11	Sahltech I Göteborg AB	Behandlung von ischämischen Gehirnschäden mit Wachstumshormon-Sekretionsförderern
JP5702288B2 (ja)	2008-09-18	2015-04-15	ノースウエスタンユニバーシティ	Ｎｍｄａレセプターモジュレータ及びその用途
US8951968B2 (en)	2009-10-05	2015-02-10	Northwestern University	Methods of treating depression and other related diseases
AU2011215704B2 (en)	2010-02-11	2015-07-23	Northwestern University	Secondary structure stabilized NMDA receptor modulators and uses thereof
KR101692275B1 (ko)	2010-02-11	2017-01-04	노오쓰웨스턴 유니버시티	２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
CA2899010A1 (en)	2013-01-29	2014-08-07	Naurex, Inc.	Spiro-lactam nmda receptor modulators and uses thereof
CA2898863A1 (en)	2013-01-29	2014-08-07	Naurex, Inc.	Spiro-lactam nmda receptor modulators and uses thereof
MX375286B (es)	2013-01-29	2025-03-06	Aptinyx Inc	Moduladores de receptores nmda de espiro-lactama y sus usos.
LT2951183T (lt)	2013-01-29	2019-05-27	Aptinyx Inc.	Spiro-laktamo nmda receptorių moduliatoriai ir jų panaudojimas
AU2014212501A1 (en)	2013-01-29	2015-07-30	Aptinyx, Inc.	Spiro-lactam NMDA receptor modulators and uses thereof
WO2017201285A1 (en)	2016-05-19	2017-11-23	Aptinyx Inc.	Spiro-lactam nmda receptor modulators and uses thereof
JP6823083B2 (ja)	2016-05-19	2021-01-27	アプティニックスインコーポレイテッド	スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
AU2017306158B2 (en)	2016-08-01	2021-10-14	Aptinyx Inc.	Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof
EA201990424A1 (ru)	2016-08-01	2019-08-30	Аптиникс Инк.	Спиролактамовые модуляторы nmda-рецептора и их применение
ES2974090T3 (es)	2016-08-01	2024-06-25	Tenacia Biotechnology Hong Kong Co Ltd	Moduladores de NMDA de espirolactama y métodos de uso de los mismos
PE20190504A1 (es)	2016-08-01	2019-04-10	Aptinyx Inc	Moduladores del receptor nmda espiro-lactam y uso de los mismos
MX385336B (es)	2016-08-01	2025-03-18	Aptinyx Inc	Moduladores del receptor nmda espiro-lactam y uso de los mismos.
JP7210599B2 (ja)	2018-01-31	2023-01-23	アプティニックスインコーポレイテッド	スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用
US12012413B2 (en)	2019-11-11	2024-06-18	Tenacia Biotechnology (Hong Kong) Co., Limited	Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5017557A (en) *	1987-07-24	1991-05-21	Industria Farmaceutica Serono S.P.A.	Treatment of infertility with somatotrophin releasing factor
SE8703625D0 (sv) *	1987-09-18	1987-09-18	Kabivitrum Ab	New medical use
US5126324A (en) *	1990-06-07	1992-06-30	Genentech, Inc.	Method of enhancing growth in patients using combination therapy
DE69218948T2 (de) *	1991-08-01	1997-07-31	Auckland Uniservices Ltd	IGF-I zur Verbesserung der neuronale Lage

1993
- 1993-05-14 SE SE19939301667A patent/SE9301667D0/xx unknown
1994
- 1994-05-16 DK DK94916460T patent/DK0697886T3/da active
- 1994-05-16 JP JP52470594A patent/JP3819932B2/ja not_active Expired - Fee Related
- 1994-05-16 NZ NZ266559A patent/NZ266559A/xx unknown
- 1994-05-16 DE DE69433058T patent/DE69433058T2/de not_active Expired - Fee Related
- 1994-05-16 AU AU68108/94A patent/AU685123B2/en not_active Ceased
- 1994-05-16 ES ES94916460T patent/ES2204916T3/es not_active Expired - Lifetime
- 1994-05-16 WO PCT/SE1994/000454 patent/WO1994026301A1/en not_active Ceased
- 1994-05-16 EP EP94916460A patent/EP0697886B1/de not_active Expired - Lifetime
- 1994-05-16 CA CA002162924A patent/CA2162924C/en not_active Expired - Fee Related
- 1994-05-16 AT AT94916460T patent/ATE247481T1/de not_active IP Right Cessation
1995
- 1995-11-09 US US08/549,798 patent/US5804550A/en not_active Expired - Fee Related
2002
- 2002-02-26 US US10/087,011 patent/US20020115594A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JPH08510214A (ja)	1996-10-29
EP0697886B1 (de)	2003-08-20
AU6810894A (en)	1994-12-12
DK0697886T3 (da)	2003-10-20
NZ266559A (en)	2000-12-22
DE69433058T2 (de)	2004-06-03
CA2162924C (en)	2008-12-30
DE69433058D1 (de)	2003-09-25
EP0697886A1 (de)	1996-02-28
AU685123B2 (en)	1998-01-15
US5804550A (en)	1998-09-08
CA2162924A1 (en)	1994-11-24
JP3819932B2 (ja)	2006-09-13
SE9301667D0 (sv)	1993-05-14
WO1994026301A1 (en)	1994-11-24
ES2204916T3 (es)	2004-05-01
US20020115594A1 (en)	2002-08-22

Legal Events

Date	Code	Title	Description
2004-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69433058D1 (de)	2003-09-25	Neuartige peptidantagonisten der glutaminsäure- und nmda-rezeptoren
FI960727A0 (fi)	1996-02-16	Neurokiniiniantagonisteina käyttökelpoiset heterosyklit
DE69033308D1 (de)	1999-11-04	Decahydro-isochinolin-derivate
ES2135414T3 (es)	1999-11-01	Antagonistas del receptor 5-ht4.
TR200101398T2 (tr)	2001-09-21	Pirolidin türevleri-CCR-3 reseptörü antagonistleri.
ID28003A (id)	2001-05-03	Turunan-turunan adamantana
UA27741C2 (uk)	2000-10-16	Похідні [2-(аміно-3,4-діоксо-1-циклобутен-1-іл)-аміно]-алкілових кислот для запобігання конвульсій і нейродегенеративних розладів та спосіб запобігання конвульсій та нейродегенеративних розладів
ES2091877T3 (es)	1996-11-16	Uso de antagonistas de la angiotensina ii para la fabricacion de un medicamento para el tratamiento de la hiperuricemia.
ATE86247T1 (de)	1993-03-15	3-indolpyruvsaeure-derivate und deren verwendung als arznemittel.
BG101806A (bg)	1998-04-30	Индолови производни като антагонисти на 5-нт рецептори
DK0869808T3 (da)	2006-11-13	Anvendelse af Glu-Trp-dipeptider til fremstilling af et lægemiddel til behandling af forskellige tilstande, der involverer neovaskularisation
DE69623634D1 (de)	2002-10-17	Pharmazeutische zusammensetzung von l-dopa ethyl ester
SE9704545D0 (sv)	1997-12-05	Novel compounds
TR199700653A2 (xx)	1998-02-21	N-(4-aril-tiazol-2-il)-sulfonamid t�revleri ve onlar�n kullan�m�.
EA199800376A1 (ru)	1998-10-29	Антагонисты рецепторов возбудительной аминокислоты
DK0561941T3 (da)	1995-03-06	N-Substituerede lactamer anvendelige som cholecystokinin-antagonister
MX9801987A (es)	1998-08-30	Nuevos derivados de aminoacido, su obtencion y su uso.
TR199900486T2 (xx)	1999-06-21	Aziniloksi ve fenoksi-diaril-karbonasit t�revleri.
ATE87918T1 (de)	1993-04-15	Tetrazolverbindungen als antagonisten der excitatorischen aminosaeurerezeptoren.
DE69621799D1 (de)	2002-07-18	Verwendung von gabapentin und seine derivate in der behandlung von manie und bipolare störungen
TR199700834T1 (xx)	1998-01-21	1-Aril-2-Akilamino ethan bile�ikleri ve bunlar�n n�rokinin olarak �zellikle n�rokinin 1 has�mlar� olarak kullan�mlar�.
ES2135412T3 (es)	1999-11-01	Uso de antagonistas o agonistas parciales del receptor 5-ht 1a para el tratamiento y la prevencion de trastornos cognitivos.
TR200000697T2 (tr)	2001-01-22	İkame edilmiş 1,2,3,4,5,6-Heksahidro-2,6-Metano-3-Benzazosin-10-OL'ler, üretim yöntemleri ve farmasötik preparat olarak kullanımları.
EA199800380A1 (ru)	1998-10-29	Антагонисты рецептора возбуждающих аминокислот
ATE285772T1 (de)	2005-01-15	Verwendung von indol-2,3-dione-3-oximderivate als ampa-antagonisten